Answers are grounded in this paper and cite their sources.
Dear Editor, While cutaneous T‐cell lymphoma (CTCL) presents most commonly with a CD4+ phenotype, CD8+ and CD30+ variants have also been described. CD8+ variants include primary cutaneous epidermotropic cytotoxic T‐cell lymphoma, subcutaneous panniculitis‐like T‐cell lymphoma, cutaneous CD8+ lymphomas associated with immunodeficiency, and CD8+ variants of other well‐defined CTCLs.1 While the epidemiology of other CTCLs has been well described, there remains a dearth of literature characterizing the incidence and survival patterns of CD8+ CTCL.2 Thus, we aimed to better characterize the data on US national epidemiological trends of this diverse group of malignancies using the Surveillance, Epidemiology and End Results (SEER) database. In our study, the primary outcomes were overall survival and disease‐specific survival (OS and DSS), and univariate and multivariate Cox proportional hazards models were used to assess relationships of reported characteristics with OS and DSS. We received full‐review exemption by the Yale Human Investigation Committee, IRB#2000027808. Detailed methods and further data are available on direct request. Our cohort comprised 1271 individuals diagnosed with CD8+ CTCL over a 6‐year period (2010–16). The median age at diagnosis was 62 years and the mean was 61·5 (range 18–100) years. Our data revealed predominance in males (55·9%) and in individuals of white race (83·1%). Age‐standardized incidence rates for our study period were 2·68 per 1 000 000 person‐years, 2·66 per 1 000 000 person‐years for white and 3·99 per 1 000 000 person‐years for black patients. The majority lived in urban areas (42·4%) and 65·7% were married. Cases presented predominantly at stage I (75·4%). Lesions were located on the face (32·6%), trunk (31·1%), and extremities (36·2%). With regard to treatment, 29·2% of patients received surgical management; chemotherapy and radiation are not well coded and therefore are not included here. OS and DSS were, respectively, 88·9% and 94·5% at 1 year, and 72·1% and 85·5% at 5 years. Survival was found to be significantly different between disease stages I and IV, with improved survival with diagnosis at stage I (P < 0·0001) (Figure 1). In univariate analysis, age [OS‐HR (hazard ratio) 1·06 (1·05–1·07); DSS‐HR 1·04 (1·02–1·37)], stage [OS‐HR 1·57 (1·43–1·74); DSS‐HR 1·86 (1·61–2·15)], lesion location and surgery [OS‐HR 0·46 (0·33–0·63); DSS‐HR 0·38 (0·23–0·63)] were prognosticators for OS and DSS, and black race [HR 1·69 (1·12–2·55)] for DSS. In risk‐adjusted models, advanced age [OS‐HR 1·08 (1·06–1·09); DSS‐HR 1·06 (1·03–1·09)], black race [OS‐HR 1·73 (1·00–3·00)] and advanced stage [OS‐HR 1·64 (1·38–1·96); DSS‐HR 1·79 (1·39–2·31)] were independent predictors of poorer survival outcomes, while lesion location on the face [DSS‐HR 0·38 (0·15–0·97)] and surgical intervention [OS‐HR 0·51 (0·32–0·84)] were associated with improved outcomes (Table 1). Factors associated with overall and disease‐specific survival on multivariate analysisa CI, confidence interval; HR, hazard ratio. a Categories in parentheses define the strata that the HR represents; variables were chosen for the multivariate model with forward and backwards stepwise selection (entry of 0·3, stay 0·15). Factors associated with overall and disease‐specific survival on multivariate analysisa CI, confidence interval; HR, hazard ratio. a Categories in parentheses define the strata that the HR represents; variables were chosen for the multivariate model with forward and backwards stepwise selection (entry of 0·3, stay 0·15). Overall, our results suggest that patients with CD8+ CTCL typically present later in life and with slight predominance in males, reflecting previously reported demographics of CTCL.3 We found that advanced age was an independent predictor for poorer outcomes. Age‐related alterations in the immune system are not only suggested to be involved in the pathogenesis of CTCL, but may also be associated with the development of more aggressive disease and decreased clearance of disease. Disease presented most commonly at stage I, and diagnosis at stage I demonstrated survival benefit. Our report demonstrates that lesions presenting on the face demonstrate better DSS. Aggressive variants of CD8+ CTCL (i.e. aggressive epidermotropic cytotoxic T‐cell lymphoma) have a propensity to involve distal anatomic sites, and our data suggests an epidemiological trend of poor survival in such advanced disease.4 We found that the majority of CD8+ CTCL cases occurred in individuals of white race, and black race was a predictor for poorer outcomes. This incidence correlates to previously reported data for CTCL occurring more commonly in individuals of black race.5 The poorer OS seen in individuals of black race reflects data that have shown black race as a risk factor for worsened mortality outcomes in CTCL,6 and we now show a racial disparity in survival outcomes for CD8+ CTCLs as well. Limitations of our study and the SEER database include the potential for absent or incorrect reporting of retrospective data, variations in coding practices, and migration of patients in or out of the database. Limiting our study to 2010–16 helps mitigate some of these concerns, and removing historic, death‐certificate and pathology‐only cases was used to limit the number of not‐otherwise‐specified CTCL cases as per the SEER abstractor notes.7 Nonetheless, the major limitation of our study is that the subtypes of CD8+ CTCL cannot be extracted from the SEER database. It has been well described that CD8+ CTCLs are a group of diseases with distinct histopathology and clinical behaviour.4 The majority of studies to date are single‐institution case reports and series, and there is a need for national and even international‐level studies to further the understanding of these rare malignancies. While our study attempts to begin to address this at a national level with current publicly available data, additional studies, particularly utilizing the developing PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) database,8 may further inform us of the clinical course and prognosis of those with various subtypes of CD8+ CTCL. Fatima Nadeem Mirza: Conceptualization (equal); Data curation (equal); Formal analysis (lead); Investigation (lead); Methodology (lead); Project administration (equal); Validation (equal); Visualization (equal); Writing‐original draft (equal); Writing‐review & editing (equal). Sara Yumeen: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Validation (equal); Visualization (equal); Writing‐original draft (lead); Writing‐review & editing (equal). Michael Girardi: Conceptualization (lead); Methodology (equal); Project administration (equal); Resources (lead); Supervision (lead); Writing‐review & editing (lead). (a) Overall and (b) disease‐specific survival stratified by stage.
No takes yet. Share an insight, caveat, or question.
Mirza et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: